🇺🇸 FDA
Pipeline program

low-dose tenecteplase intravenous thrombolysis

2025IITDA10

Approved small_molecule active

Quick answer

low-dose tenecteplase intravenous thrombolysis for Acute Ischemic Stroke Patients is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Acute Ischemic Stroke Patients
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials